TITLE:
The Aryl Hydrocarbon Receptor: A Target for Breast Cancer Therapy
AUTHORS:
Joann B. Powell, Gennifer D. Goode, Sakina E. Eltom
KEYWORDS:
Aryl Hydrocarbon Receptor; Therapeutic Targeting; Breast Cancer Progression; Chemosensitization
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.4 No.7,
August
22,
2013
ABSTRACT: The aryl hydrocarbon receptor (AhR) is
a ligand-activated transcription factor that regulates a battery of genes in response to exposure to a broad class of
environmental poly aromatic hydrocarbons (PAH). AhR is historically characterized
for its role in mediating the toxicity and adaptive responses to these
chemicals, however mounting evidence has established a role for it in
ligand-independent physiological processes and pathological conditions,
including cancer. The AhR is overexpressed and constitutively activated in
advanced breast cancer cases and was shown to drive the progression of breast
cancer. In this article we will review the current state of knowledge on the
possible role of AhR in breast cancer and how it will be exploited in targeting AhR for
breast cancer therapy.